The risks of cardiovascular events for people with type 2 diabetes could be reduced with a new treatment, research suggests.
Experts welcomed the “encouraging data” presented by the International Diabetes Federation 21st World Diabetes Congress, which analysed three previously published clinical studies.
It demonstrated that people with type 2 diabetes taking Januvia (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events compared with those treated with a sulphonylurea (SU).
The studies involved people with type 2 diabetes randomised to receive sitagliptin 100mg/day or an SU as monotherapy, or as an add on to metformin.
There were no reports of major CV events (defined as ischaemic events or CV death) in the sitagliptin arm and 11 reports of patients experiencing at least one major CV event in the SU group.
Glasgow Royal Infirmary associate professor and consultant cardiologist Dr Adrian Brady said the research data provided “an important consideration” in how patients are managed to minimise the risk of cardiovascular disease.